Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
A newly reported side effect of the popular GLP-1 weight loss drugs may be its most annoying yet
Next-generation agents include CagriSema (semaglutide + cagrilintide, NDA filed December 2025, showing 22.7% weight loss), retatrutide (triple GIP/GLP-1/glucagon agonist, 28.7% weight loss in Phase 3), and orforglipron (oral non-peptide GLP-1, submitted to FDA)
C.Di BenedettoG.ScorranoL
Research shows BPC-157 helps safeguard and repair the intestinal lining, which may be valuable for conditions like: Irritable bowel issues Leaky gut and food sensitivities Inflammation-driven gut damage Unlike antacids or symptom-based medications, BPC-157 appears to restore structural integrity to the gut barrier, helping address root causes rather than simply easing discomfort
Multiple studies have shown that tirzepatide can lead to substantial weight loss
GPR37 promotes colorectal cancer liver metastases by enhancing the glycolysis and histone lactylation via Hippo pathway
US$ 21.31
US$ 20.71
US$ 22.88
US$ 29.04
US$ 25.23
US$ 20.37
US$ 24.03
-1775582746855.png&w=3840&q=75)
US$ 20.03
US$ 21.16
US$ 24.88
